BlackRock
BHVN

BlackRock’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

BlackRock’s Portfolio BHVN Stock Details BHVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-4,949,917
Closed -$748M – 6014
2022
Q3 		$748M Sell
4,949,917
-122,158
-2% -$18.1M 0.03% 602
2022
Q2 		$739M Buy
5,072,075
+415,209
+9% +$53M 0.02% 627
2022
Q1 		$552M Buy
4,656,866
+21,586
+0.5% +$2.69M 0.01% 899
2021
Q4 		$639M Buy
4,635,280
+28,207
+0.6% +$3.59M 0.02% 850
2021
Q3 		$640M Sell
4,607,073
-84,505
-2% -$10.6M 0.02% 811
2021
Q2 		$455M Buy
4,691,578
+908,024
+24% +$73.7M 0.01% 1089
2021
Q1 		$259M Buy
3,783,554
+258,603
+7% +$20.9M 0.01% 1536
2020
Q4 		$302M Buy
3,524,951
+76,411
+2% +$6.47M 0.01% 1303
2020
Q3 		$224M Sell
3,448,540
-82,786
-2% -$5.43M 0.01% 1296
2020
Q2 		$258M Buy
3,531,326
+260,157
+8% +$13.8M 0.01% 1170
2020
Q1 		$111M Buy
3,271,169
+352,828
+12% +$16.1M 0.01% 1574
2019
Q4 		$159M Buy
2,918,341
+16,218
+0.6% +$803K 0.01% 1665
2019
Q3 		$121M Buy
2,902,123
+411,603
+17% +$17.4M 0.01% 1779
2019
Q2 		$109M Sell
2,490,520
-368,373
-13% -$20.8M ﹤0.01% 1846
2019
Q1 		$147M Buy
2,858,893
+465,745
+19% +$20.1M 0.01% 1636
2018
Q4 		$88.5M Buy
2,393,148
+225,386
+10% +$8.13M ﹤0.01% 1889
2018
Q3 		$81.4M Buy
2,167,762
+77,374
+4% +$2.85M ﹤0.01% 2099
2018
Q2 		$82.6M Buy
2,090,388
+201,780
+11% +$6.4M ﹤0.01% 2066
2018
Q1 		$48.6M Buy
1,888,608
+734,401
+64% +$22M ﹤0.01% 2282
2017
Q4 		$31.1M Buy
1,154,207
+12,505
+1% +$344K ﹤0.01% 2541
2017
Q3 		$42.7M Buy
1,141,702
+120,770
+12% +$3.66M ﹤0.01% 2376
2017
Q2 		$25.5M Buy
+1,020,932
New +$23.5M ﹤0.01% 2659

Other funds holding BHVN

LIP
Liontrust Investment Partners London, United Kingdom $5.86B AUM 23.75% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
MSCM
McElhenny Sheffield Capital Management Dallas, Texas $403M AUM 28.73% 1-Year Est. Return

BlackRock's BHVN Position: Q4 2022 in Review

BlackRock sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q4 2022, closing a stake of 4,949,917 shares — an estimated $748M sold.

BlackRock first reported a position in BHVN in Q2 2017 and held it in 22 quarters. The position peaked at $748M in Q3 2022. 7 funds tracked by Wall St. Rank hold BHVN as of Q4 2022.

  • BlackRock reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q4 2022 after selling out during the quarter.
  • BlackRock sold 4,949,917 Biohaven Pharmaceutical Holding Company Ltd. shares in Q4 2022, an estimated $748M.
  • BlackRock first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q2 2017 and held it in 22 quarters.
  • BlackRock's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $748M in Q3 2022.
  • 7 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q4 2022.

Based on BlackRock's 13F filing for Q4 2022, filed 13 Feb 2023.